Scarica l'app Stockscreener
103.36
1.78%
-1.87
Dopo l'orario di chiusura:
103.00
-0.36
-0.35%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$105.23
Aprire:
$105.18
Volume 24 ore:
7.75M
Relative Volume:
0.71
Capitalizzazione di mercato:
$178.85B
Reddito:
$46.59B
Utile/perdita netta:
$5.41B
Rapporto P/E:
33.41
EPS:
3.0938
Flusso di cassa netto:
$7.38B
1 W Prestazione:
-4.99%
1M Prestazione:
-4.84%
6M Prestazione:
-6.50%
1 anno Prestazione:
-20.10%
Intervallo 1D:
$103.18
$105.19
Intervallo di 1 settimana:
$103.18
$110.01
Portata 52W:
$81.97
$137.49
Abbott Laboratories Stock (ABT) Company Profile
Nome
Abbott Laboratories
Settore
Industria
Telefono
(224) 667-6100
Indirizzo
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT vs MDT, SYK, BSX, EW
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
103.36 | 182.09B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
91.62 | 117.54B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
270.01 | 105.63B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
43.10 | 65.16B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.77 | 49.67B | 6.30B | 1.07B | 1.09B | 1.8406 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-22 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2025-10-10 | Iniziato | The Benchmark Company | Buy |
| 2025-07-18 | Aggiornamento | Jefferies | Hold → Buy |
| 2025-06-16 | Iniziato | Leerink Partners | Market Perform |
| 2024-10-08 | Iniziato | Oppenheimer | Outperform |
| 2024-09-19 | Iniziato | Piper Sandler | Overweight |
| 2024-07-30 | Downgrade | Edward Jones | Buy → Hold |
| 2024-05-30 | Iniziato | Goldman | Buy |
| 2023-07-21 | Aggiornamento | Wolfe Research | Underperform → Peer Perform |
| 2023-05-30 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2023-04-20 | Reiterato | Barclays | Overweight |
| 2023-04-20 | Reiterato | Bernstein | Outperform |
| 2023-04-20 | Reiterato | JP Morgan | Overweight |
| 2023-04-20 | Reiterato | Raymond James | Outperform |
| 2023-04-20 | Reiterato | UBS | Buy |
| 2023-04-20 | Reiterato | Wolfe Research | Underperform |
| 2023-03-29 | Iniziato | UBS | Buy |
| 2022-10-26 | Iniziato | Mizuho | Neutral |
| 2022-10-18 | Iniziato | Barclays | Overweight |
| 2022-10-12 | Iniziato | Jefferies | Hold |
| 2022-07-06 | Iniziato | Wolfe Research | Underperform |
| 2022-03-02 | Ripresa | BofA Securities | Buy |
| 2022-01-27 | Reiterato | Credit Suisse | Outperform |
| 2022-01-27 | Reiterato | Morgan Stanley | Overweight |
| 2022-01-27 | Reiterato | Raymond James | Outperform |
| 2022-01-27 | Reiterato | UBS | Buy |
| 2021-12-10 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-10-27 | Aggiornamento | Atlantic Equities | Neutral → Overweight |
| 2021-10-14 | Iniziato | Redburn | Neutral |
| 2021-05-25 | Iniziato | Barclays | Overweight |
| 2021-04-15 | Iniziato | Atlantic Equities | Neutral |
| 2021-01-28 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2020-09-11 | Iniziato | Wolfe Research | Outperform |
| 2020-06-01 | Downgrade | Goldman | Neutral → Sell |
| 2020-03-05 | Iniziato | Citigroup | Buy |
| 2020-02-13 | Iniziato | Goldman | Neutral |
| 2020-02-06 | Ripresa | BTIG Research | Neutral |
| 2020-01-02 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-06-13 | Reiterato | BofA/Merrill | Buy |
| 2019-02-07 | Reiterato | BofA/Merrill | Buy |
| 2019-01-02 | Downgrade | Citigroup | Neutral → Sell |
| 2018-11-30 | Aggiornamento | Goldman | Neutral → Buy |
| 2018-10-16 | Iniziato | Barclays | Overweight |
| 2018-06-27 | Iniziato | Bernstein | Outperform |
| 2018-01-30 | Reiterato | Citigroup | Neutral |
| 2018-01-25 | Reiterato | Stifel | Buy |
| 2018-01-25 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2018-01-03 | Iniziato | Evercore ISI | Outperform |
| 2018-01-02 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2018-01-02 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2017-10-19 | Reiterato | RBC Capital Mkts | Outperform |
| 2017-10-19 | Reiterato | Stifel | Buy |
Mostra tutto
Abbott Laboratories Borsa (ABT) Ultime notizie
Top Research Reports for Goldman Sachs, RTX & Abbott - Yahoo Finance
Abbott Laboratories Share Price Today (ABT) | Live Chart, News & Stock Market - TechGraph
Abbott Spinal Cord Stimulator Explant Surgery Required After Device Failure: Lawsuit - AboutLawsuits.com
Abbott Laboratories stock falls after FDA approval - ad-hoc-news.de
Abbott Laboratories stock before the bell falls 2.6 percent - ad-hoc-news.de
Abbott Laboratories (ABT) Secured FDA Approval, Is It Still 11% Below Fair Value? - simplywall.st
Abbott Wins FDA Clearance for Dual-Energy AFib Catheter - finance.biggo.com
Abbott partners with Sengkang General Hospital to advance early detection of muscle loss in Singapore - BioSpectrum Asia
Abbott Is Selling Sterility as a Feature. In Liquid Formula It Is Already the Rule. - marlerblog.com
Abbott Receives FDA Nod for TactiFlex Duo: Stock to Gain? - Yahoo Finance
Abbott garners FDA nod for its TactiFlex catheter to treat AFib - Fierce Biotech
Abbott’s dual ablation catheter lands FDA approval - Yahoo Finance
Abbott Laboratories stock gains after FDA approval and strong guidance - ad-hoc-news.de
Abbott Laboratories stock heads into the open after a modest loss - ad-hoc-news.de
Here's Why Abbott (ABT) Fell More Than Broader Market - Yahoo Finance
Abbott Laboratories stock underperforms Tuesday when compared to competitors - MarketWatch
1 No-Brainer ETF I'm Loading Up on in 2026 and Beyond - The Motley Fool
FDA approves new Abbott catheter capable of PFA and radiofrequency ablation - Cardiovascular Business
Abbott wins FDA approval for dual-energy ablation catheter - MedTech Dive
Abbott receives FDA approval for AFib ablation catheter - grafa.com
Abbott Laboratories (ABT) Won FDA Approval For Its TactiFlex Duo Catheter - simplywall.st
Abbott scores another win at UPC with SiBio preliminary injunction - IAM Patent
Abbott receives FDA approval for dual-energy heart ablation catheter By Investing.com - Investing.com Canada
Abbott wins FDA nod for cardiac ablation catheter (ABT:NYSE) - Seeking Alpha
The FDA Clears an Abbott Product - marketscreener.com
Abbott receives FDA approval for its TactiFlex™ Duo Ablation Catheter to treat people with abnormal heart rhythms - PR Newswire
Abbott Laboratories stock holds firm after July earnings - AD HOC NEWS
Abbott Laboratories (NYSE:ABT): Can Heart Research Lift Its Next Move? - Kalkine Media
Abbott Blocks Rival's Glucose Monitor Sales In Europe - Law360
Abbott Laboratories stock holds valuation premium amid steady earnings - ad-hoc-news.de
Abbott Laboratories (ABT) Stock Analysis: Analyst Consensus Reveals a 10.96% Upside Potential - DirectorsTalk Interviews
Abbott Stock And Other Defensive Dividend Picks For Uncertain Markets - simplywall.st
Abbott Laboratories stock holds near $108 after strong Q2 - AD HOC NEWS
Abbott Laboratories Profile: Recipients - OpenSecrets
Abbott Laboratories (ABT) Q2 2026 Earnings Call Transcript - Fortune
How New Diabetes, Cardiac, Nutrition and Cancer Tools At Abbott Laboratories (ABT) Have Changed Its Investment Story - simplywall.st
Abbott CFO Philip P. Boudreau Retains 70,784 Shares After Forfeiting 388 Shares at $110.36 Each - Kalkine Media
Ferguson Wellman Capital Management Inc. Sells 136,385 Shares of Abbott Laboratories $ABT - InsuranceNewsNet
Renal Denervation Market Size, Share & Trends Analysis - GlobeNewswire Inc.
US companies face rise in cyber attacks - Reuters
Abbott Laboratories CFO Philip P. Boudreau Reports Sale of 388 Shares at $110.36 in SEC Form 4 Filing - Kalkine Media
Abbott Laboratories VP John A. McCoy Jr. Reports Share Sales on September 1-2, 2026 - Kalkine Media
Abbott Laboratories (ABT) CFO reports small tax-related share disposal - Stock Titan
Abbott Laboratories stock underperforms Thursday when compared to competitors - MarketWatch
Abbott Laboratories stock gains support from fresh earnings and guidance - AD HOC NEWS
Abbott ablation device effective at 1 year in complex cases - MedTech Dive
Small Abbott (NYSE: ABT) insider sale from vested stock award - Stock Titan
Abbott Laboratories stock underperforms Wednesday when compared to competitors despite daily gains - MarketWatch
Abbott settlement and Kendamil case add to formula industry scrutiny - FoodNavigator.com
J.P. Morgan Maintains Abbott Laboratories(ABT.US) With Buy Rating - Moomoo
Abbott Introduces America’s First Liquid Baby Formula With Whole Milk - Yahoo Finance
Abbott Laboratories Azioni (ABT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.29%
0.68%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):